Patents Represented by Attorney Arnold & Porter LLP

Find this attorney in the Justia Lawyer Directory

  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 7858330
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen D. Frantz, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Materials and methods for treatment of cancer
    Patent number: 7855182
    Abstract: Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumors which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: December 21, 2010
    Assignee: The Institute of Cancer Research; Royal Cancer Hospital
    Inventors: Janet Shipley, Daniel Williamson, Jane Renshaw, Rosanne Orr
  • Method of treating breast cancer using anti-HER2 antibody variants
    Patent number: 7850966
    Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: December 14, 2010
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
  • Porous media
    Patent number: 7846333
    Abstract: A porous media, a housing containing a porous media and methods for fabricating the housing containing a porous media are provided. The porous media is composed of varying amounts of sorptive binding particles in combination with polymer particles, for example silica particles mixed with polyethylene beads. The porous media is sintered into target housings, for example pipette tips, for use in desalting, purifying and separating biomolecules in target samples. The porous media is also formed into porous media discs via pressure and heating for insertion into housing devices.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: December 7, 2010
    Inventors: Wilhelm Pluester, Christian Ziegmann
  • Methods of stimulating ErbB4 receptor phosphorylation
    Patent number: 7846453
    Abstract: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: December 7, 2010
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Melanie Rose Mark, Dong Xiao Zhang
  • Cloning of honey bee allergen
    Patent number: 7846690
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to expression vectors, host cells and polypeptides encoded by the nucleic acid, as well as diagnostic and pharmaceutical uses thereof.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: December 7, 2010
    Assignee: PLS-Design GmbH
    Inventor: Thomas Grunwald
  • Recombinant polypeptides associated with plants
    Patent number: 7834146
    Abstract: Recombinant polynucleotides and recombinant polypeptides useful for improvement of plants are provided. The disclosed recombinant polynucleotides and recombinant polypeptides find use in production of transgenic plants to produce plants having improved properties.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: November 16, 2010
    Assignee: Monsanto Technology LLC
    Inventors: David K. Kovalic, Yihua Zhou, Yongwei Cao, Scott E. Andersen, Michael D. Edgerton, Jingdong Liu
  • Phosphorus-containing thyromimetics
    Patent number: 7829552
    Abstract: The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: November 9, 2010
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
  • Phosphorus-containing prodrugs
    Patent number: 7816345
    Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: October 19, 2010
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
  • Polymeric modifiers and pharmaceutical compositions
    Patent number: 7811556
    Abstract: A copolymer or a pharmacologically acceptable salt thereof is provided, which contains, as constitutional units, (a) one or more structural units of formula (I): wherein m is an integer of from 3 to 100, Alk represents alkyline, and R1 and R2 are the same or different and each represents hydrogen or optionally substituted alkyl, and (b) one or more structural units of formula (II): wherein R3 represents hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, or a group represented by the formula —NR4R5, wherein R4 and R5 are the same or different and each represents hydrogen or optionally substituted alkyl.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: October 12, 2010
    Assignee: Sankyo Company, Limited
    Inventors: Yuji Kasuya, Masashi Honma
  • Conductive media for electrophoresis
    Patent number: 7811437
    Abstract: A series of low molarity conductive media based on non-buffering univalent cations, such as sodium chloride-sodium acetate (SCA), sodium boric acid (SB), lithium boric acid, and lithium acetate mitigate the “runaway” positive feedback heating loop produced by conventional media containing biological amine buffers and permit improved DNA electrophoresis under the conditions of low salt concentration. These media serve well in ultra-fast DNA electrophoresis and in high-resolution separations of RNA and DNA fragments.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: October 12, 2010
    Assignee: Faster Better Media LLC
    Inventors: Scott E. Kern, Jonathan R. Brody
  • Analytical method
    Patent number: 7811773
    Abstract: The instant invention describes an analytical assay to accurately measure an analyte in the presence of an interfering substance.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc.
    Inventor: Peter Ralph
  • Engineering ?-ketoacyl ACP synthase for novel substrate specificity
    Patent number: 7812220
    Abstract: Methods of altering substrate specificity of beta-ketoacyl-ACP synthase, and engineered beta-ketoacyl-ACP synthases so produced are provided. DNA sequences and constructs for expression of engineered beta-ketoacyl-ACP synthases, as well as the novel beta-ketoacyl-ACP synthases produced therefrom are also provided. Such DNA sequences may be used for expression of the engineered beta-ketoacyl-ACP synthases in host cells, particularly seed cells of oilseed crop plants, for the modification of fatty acid composition.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: October 12, 2010
    Assignee: Calgene LLC
    Inventors: Katayoon Dehesh, Dale Val
  • Reducing protein A leaching during protein A affinity chromatography
    Patent number: 7807799
    Abstract: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: October 5, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert L. Fahrner, Amy Laverdiere, Paul J. McDonald, Rhona M. O'Leary
  • Tomato plants that exhibit resistance to
    Patent number: 7799976
    Abstract: The present invention relates to tomato plants that exhibit resistance to Botrytis cinerea and methods for developing new inbreds, hybrid, apomictic and genetically engineered tomato plants that possess resistance to Botrytis cinerea and having commercially desirable characteristics.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: September 21, 2010
    Assignees: Seminis Vegetable Seeds, Inc., Cornell Research Foundation, Inc.
    Inventors: Brad Kane Gabor, Anna Julia Frampton, Mauro Bragaloni, Steven D. Tanksley
  • Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
    Patent number: 7795504
    Abstract: The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with simultaneous up- and down-regulation of expression of RNAs. Specifically it includes methods of simultaneously enhancing the expression of a first RNA at the same time as suppressing the expression of a second RNA. The present invention also specifically provides constructs capable of simultaneously enhancing the expression of a first RNA while at the same time suppressing the expression of a second RNA, methods for utilizing such agents and plants containing such agents. The present invention also provides other constructs including polycistronic constructs.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: September 14, 2010
    Assignee: Monsanto Technology LLC
    Inventors: Alison Van Eenennaam, Christine K. Shewmaker
  • Membrane-anchored GP41 peptides that inhibit subsequent HIV viral entry
    Patent number: 7790870
    Abstract: The invention relates to the genetically engineered treatment of an HIV infection by the expression of membrane-anchored gp41 peptides. With this treatment vectors are made available for the first time which code for a fusion protein that contains a peptide derived from gp41 of HIV and a carboxy terminal by means of a trans-membrane anchor tagged to a flexible linker.
    Type: Grant
    Filed: November 24, 2000
    Date of Patent: September 7, 2010
    Assignee: Heinrich-Pette-Institut
    Inventor: Meike-Dorothee von Laer
  • Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
    Patent number: 7771719
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: August 10, 2010
    Assignee: Genentech, Inc.
    Inventors: Ellen H. Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Microtitration plate
    Patent number: 7767153
    Abstract: A microtitration plate has a frame (2) made of a first stiff plastic and having a plate (4) with multiplicity of holes (2?), and a multiplicity of vessels (3) made of a second plastic suited for the PCR and/or exhibiting permeability to oxygen, which are fixedly connected to the plate (4) by directly molding them to the holes (6), which have a receiving portion (9, 10, 11) protruding from an underside (8) of the plate (4), and which are accessible from an upper surface (7) of the plate through apertures (15).
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: August 3, 2010
    Assignee: Eppendorf AG
    Inventors: Nico Guelzow, Bernd Ohm Petersen
  • Antibodies to tumor necrosis factor receptor associated factor polypeptides
    Patent number: 7754858
    Abstract: The invention concerns antibodies to new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of tumor necrosis factor (TNF) biological activities.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Mike Rothe